BTIG Cheers as Teva Pharmaceutical Hits Corporate Reset

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has given investors news to stoke some enthusiasm after a long road of debt, exclusivity on multiple sclerosis asset Copaxone that slipped through the cracks, and a mountain of debt towering at $35 billion. With news of CEO Kare Schultz hitting the refresh button on corporate leadership as well as organizational structure, shares are soaring, leaving BTIG analyst Tim Chiang confident that this global generic pharma giant can captivate more positive attention approaching 2018.

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts